Cytosolic CRISPR RNA for RNA-targeting CRISPR-Cas systems
Abstract
Clustered regularly interspaced short palindromic repeats/CRISPR-associated protein (CRISPR/Cas) technologies have evolved rapidly over the past decade with the continuous discovery of new Cas systems. In particular, RNA-targeting CRISPR-Cas13 proteins are promising single-effector systems to regulate target mRNAs without altering genomic DNA, yet the current Cas13 systems are still restrained by suboptimal efficiencies. Here, we show that U1-driven CRISPR RNAs (crRNAs) can dramatically increase the efficiency of various applications, including RNA knockdown and editing, without modifying the Cas13 protein effectors. We confirm that U1-driven crRNAs are exported into the cytoplasm, while conventional U6 promoter-driven crRNAs are mostly confined in the nucleus. Furthermore, we reveal that the end positions of crRNAs expressed by the U1 promoter are consistent regardless of different guide sequences and lengths. We also demonstrate that U1-driven crRNAs, but not U6-driven crRNAs, can efficiently repress the translation of target genes in combination with catalytically inactive Cas13 proteins. Finally, we show that U1-driven crRNAs can counteract the inhibitory effect of miRNAs. Our simple and effective engineering enables unprecedented cytosolic RNA-targeting applications.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 6
- FWCI
- 1.49
- Field percentile
- top 20%
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Optimizing a CRISPR-Cas13d gene circuit for tunable target RNA downregulation with minimal collateral RNA cutting
Yiming Wan, Christopher Helenek, … Gábor Balázsi·ACS Synthetic BiologyPeer-reviewed·Oct 8, 2024
- Intrinsic RNA targeting constrains the utility of CRISPR-Cas13 systems
- CRISPR/Cas13 effectors have differing extents of off-target effects that limit their utility in eukaryotic cells
Yuxi Ai, Dongming Liang, Jeremy E. Wilusz·Nucleic Acids ResearchPeer-reviewed·Feb 21, 2022
- Chemically modified guide RNAs enhance CRISPR-Cas13 knockdown in human cells
A. Mendez-Mancilla, H.-H. Wessels, … N. E. Sanjana·bioRxiv·May 12, 2021
- Repurposing CRISPR-Cas13 systems for robust mRNA trans-splicing
David N. Fiflis, Nicolas A. Rey, … Aravind Asokan·Nature CommunicationsPeer-reviewed·Mar 14, 2024
- Engineering improved Cas13 effectors for targeted post-transcriptional regulation of gene expression
E. J. Charles, S. E. Kim, … D. F. Savage·bioRxiv·May 26, 2021